ANAPTYSBIO, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
ANAPTYSBIO, INC. (ANAB) had Debt Securities, Available-for-sale, Unrealized Loss Position of $24.84 million as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-09-21
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $24.84M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $140.78M.
- 2025-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $83.61M.
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $32.83M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $24.84M 10-KT · filed 2026-09-21 |
| 2025-06-30 | $140.78M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $83.61M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $32.83M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $22.43M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $257.99M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $276.45M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $238.70M 10-K · filed 2025-02-27 |
| 2023-09-30 | $412.63M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $433.73M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $327.32M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $466.91M 10-K · filed 2024-03-11 |
| 2022-09-30 | $501.92M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $464.22M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $407.75M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $108.69M 10-K · filed 2023-03-01 |
| 2021-09-30 | $7.27M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $8.26M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $10.94M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $49.11M 10-K · filed 2022-03-07 |
| 2020-09-30 | $39.32M 10-Q · filed 2020-11-04 |
| 2020-03-31 | $36.28M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $23.59M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |